Acute Hepatic Encephalopathy
Understanding Acute Hepatic Encephalopathy (HE), also known as Liver Encephalopathy or Hepatic Coma, is crucial for accurate clinical documentation and medical coding. This page provides healthcare professionals with information on diagnosing and managing Acute Hepatic Encephalopathy, including its stages, symptoms, and treatment options. Learn about relevant medical codes and best practices for documenting HE in patient charts to ensure proper care and reimbursement.
Brain dysfunction due to liver failure, causing impaired mental status and neurological symptoms.
Confusion, disorientation, tremor, asterixis, sleep disturbances, coma.
Cirrhosis, severe hepatitis, drug overdose, portal hypertension, infections.
ICD-10 Code Families
Complete code families applicable to K72.00
When to use each related code
| Description | When to use |
|---|---|
| Brain dysfunction due to liver failure. | Acute onset of altered mental status in patients with liver disease. Consider subtypes based on severity. |
| Chronic brain dysfunction due to liver failure. | Chronic or recurring episodes of cognitive impairment in patients with cirrhosis or other chronic liver diseases. |
| Worsening of hepatic encephalopathy triggered by a specific event. | Acute deterioration of mental status in a patient with pre-existing hepatic encephalopathy, often precipitated by infection, GI bleeding, or medications. |
Best-practice checklist
- ✓Document West Haven Criteria stage.
- ✓Specific neurological findings (e.g., asterixis, altered mental status).
- ✓Causative factors for acute hepatic encephalopathy documented.
- ✓Exclude other encephalopathy causes (e.g., drugs, infections).
- ✓Lab results: ammonia, LFTs, creatinine, INR.
Common pitfalls to avoid
Coding hepatic encephalopathy without specifying acuity (grade) can lead to lower reimbursement and inaccurate severity reflection.
Insufficient documentation of precipitating factors (e.g., infection, GI bleed) may impact DRG assignment and quality metrics.
Lack of clear documentation of the underlying liver disease causing the encephalopathy can hinder accurate coding and clinical analysis.
Best-practice tips
- 01Control ammonia levels: Low-protein diet, lactulose.
- 02Treat precipitating factors: Infections, GI bleeds, meds.
- 03Monitor neurologic status: Frequent mental assessments.
- 04Document detailed H&P for accurate ICD-10 coding (K72.0, K72.1).
- 05Ensure compliant CDI: AHE stage, cause, treatments.
Step-by-step checklist
- 1
Confirm elevated ammonia level (ICD-10 R72.7)
- 2
Document altered mental status (AMS) severity
- 3
Exclude other causes of encephalopathy (neuro consult)
- 4
Assess precipitating factors (infection, GI bleed)
- 5
Review medications (hepatotoxic drugs, sedatives)
Ready-to-paste narrative
Patient presents with symptoms suggestive of Acute Hepatic Encephalopathy (AHE), also known as Liver Encephalopathy or Hepatic Coma. Clinical presentation includes altered mental status, ranging from mild confusion and disorientation to stupor and coma. The patient exhibits asterixis and demonstrates impaired psychomotor skills. Laboratory findings reveal elevated ammonia levels, abnormal liver function tests (LFTs) including increased AST (aspartate aminotransferase) and ALT (alanine aminotransferase), and prolonged prothrombin time (PT). The patient's medical history includes cirrhosis, a significant risk factor for hepatic encephalopathy. Diagnostic considerations include ruling out other causes of encephalopathy, such as intracranial hemorrhage, infection, and metabolic disturbances. The current episode is likely precipitated by a recent gastrointestinal bleed, confirmed by positive fecal occult blood test. Initial management includes lactulose administration to reduce ammonia levels and supportive care to maintain hemodynamic stability. The patient will be closely monitored for neurological deterioration and potential complications, including cerebral edema and respiratory failure. Differential diagnosis includes other metabolic encephalopathies, drug-induced encephalopathy, and structural brain lesions. ICD-10 code K72.0 (Hepatic coma) and CPT codes for relevant laboratory tests and procedures will be documented for medical billing and coding purposes. Prognosis is guarded and dependent on the underlying liver disease severity and response to treatment. Further evaluation and management may include neuroimaging, EEG, and consultation with gastroenterology and critical care specialists.
Common questions and answers
What are the key clinical features differentiating the stages of acute hepatic encephalopathy in patients with cirrhosis?+
Differentiating the stages of acute hepatic encephalopathy (AHE) in patients with cirrhosis relies on recognizing subtle changes in mental status, neuromuscular function, and EEG findings. Stage 1, often missed, presents with mild confusion, shortened attention span, and subtle changes in personality or sleep patterns. Stage 2 involves lethargy, disorientation, asterixis (flapping tremor), and inappropriate behavior. Stage 3 manifests as marked confusion, somnolence but arousable patient, incoherent speech, and hyperreflexia. Stage 4, the most severe, presents as coma, absence of asterixis, and decerebrate posturing. Precise staging is crucial for determining appropriate management. Consider implementing validated clinical scales like the West Haven Criteria or the Glasgow Coma Scale to enhance diagnostic accuracy. Explore how different stages correlate with specific treatment approaches for optimal patient outcomes.
How does rifaximin compare to lactulose in managing hyperammonemia and improving cognitive function in patients with recurrent hepatic encephalopathy?+
Both rifaximin and lactulose are frequently employed in the management of recurrent hepatic encephalopathy (HE) by targeting ammonia reduction. Lactulose, a non-absorbable disaccharide, acts as a colonic acidifier, reducing ammonia production. Rifaximin, a non-absorbable antibiotic, decreases ammonia-producing gut bacteria. Studies suggest that rifaximin may be as effective as or, in some cases, superior to lactulose in reducing ammonia levels and improving cognitive function, particularly in preventing recurrent episodes. Furthermore, rifaximin may be associated with fewer side effects, especially diarrhea, compared to lactulose. Learn more about the potential benefits of combination therapy with rifaximin and lactulose for optimized ammonia control and improved quality of life in patients with recurrent HE.
What are the crucial laboratory tests for diagnosing and monitoring acute hepatic encephalopathy, and how should these results be interpreted in the context of a patient with underlying liver disease?+
Diagnosing and monitoring AHE requires a comprehensive evaluation, including essential laboratory tests. Serum ammonia levels are commonly measured, although their correlation with the severity of HE can be inconsistent. Liver function tests, including bilirubin, AST, ALT, and alkaline phosphatase, provide insights into the underlying liver disease severity. Renal function tests (creatinine, BUN) are important as renal dysfunction can exacerbate HE. Arterial blood gas analysis helps assess acid-base balance and oxygenation. Coagulation studies (PT, INR) are crucial, as coagulopathy is common in liver disease and may influence treatment options. Interpreting these results requires considering the patient's overall clinical picture, including their underlying liver disease stage and any precipitating factors for AHE. Explore how combining laboratory findings with clinical assessment provides a more accurate diagnosis and allows for targeted interventions in patients with AHE.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.